Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Purpose:

Prophylactic use of Filgrastim SD/01 for patients with Hodgkin's lymphoma receiving ABVD chemotherapy.


Criteria:

INCLUSION: - Previously untreated Hodgkin's disease patients who are scheduled to receive standard ABVD chemo. - Histologically proven diagnosis of Hodgkin's disease of any type. - Bidimensionally measurable disease. - Signed informed consent. - Age >/= 16 yrs. - Adequate bone marrow reserve (ANC>1000/uL, Platelet >100,000/uL. - LVEF>/=50% by MUGA scan or echocardiogram. - Serum creatinine <2mg/dL; serum bilirubin<2mg/dL. EXCLUSION: - HIV positive. - Pregnant women and those of child bearing age who are not using adequate contraception. - Prior chemotherapy. - Severe pulmonary disease including COPD and asthma. - History of prior sensitivity to E.coli derived products.


NCT ID:

NCT00038558


Primary Contact:

Principal Investigator
Anas Younes, MD
UT MD Anderson Cancer Center


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 16, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.